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ABSTRACT
Objective: Lactoferrin is a glycoprotein released from the secondary granules of activated neutrophils
in the setting of infection. The purpose of this study was to determine if amniotic-fluid (AF)
lactoferrin levels are elevated in preterm labor (PTL) patients with subclinical intraamniotic infec-
tion (IAI).
Methods:AF samples were obtained from 186 pregnant patients with the following characteristics:
group 1 term, no labor; group 2 preterm, no labor; group 3 PTL with IAI; group 4 PTL without
IAI. Lactoferrin levels were measured with an enzyme-linked immunosorbent assay (ELISA).
Results: AF lactoferrin levels were elevated in normal gestation after 31 weeks (P < 0.0001).
Lactoferrin levels were also higher in infected PTL patients compared with noninfected PTL
patients at gestations -<31 weeks (P 0.005). An AF lactoferrin level of >2.5 txg/ml is highly
suggestive of infection in PTL patients at <32 weeks, with an overall sensitivity of 82% and a
specificity of 83%, when infection is defined as a positive AF culture or positive placental histology.
Conclusions: AF lactoferrin levels increase after 31 weeks in normal gestations, but lactoferrin
levels >2.5 txg/ml in PTL patients before this gestational age are highly suggestive of IAI. AF
lactoferrin levels may be a useful clinical tool for selecting those PTL patients who might benefit
from antimicrobial therapy, closer observation, or early delivery. (C) 1996 Wiley-Liss, Inc.
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reterm labor (PTL) and delivery are significant
causes of perinatal mortality and morbidity. In
about 40% of cases, the underlying cause of PTL
is unclear, particularly in the setting of PTL with
intact membranes. Mounting evidence suggests an
infectious etiology for PTL by linking positive am-
niotic-flui (AF) cultures, elevated AF cytokine lev-
els, or histologic chorioamnionitis to PTL with in-
tact membranes,eq It is theorized that bacterial
invasion of the decidua, membranes, or AF stimu-
lates a maternal immune response that involves the
release of cytokines along with neutrophil activa-
tion. This immune response, in turn, initiates pros-
taglandin production and a cascade of events lead-
ing to PTL.
Lactoferrin is an iron-binding glycoprotein pres-
ent in a number of body fluids including breast
milk, sweat, tears, and plasma. It has also been
reported to be present at low levels in AF in early
pregnancy, with increasing levels in the third tri-
mester. The source of increasing lactoferrin levels
in the third trimester is thought to be decidua.z
Lactoferrin is also known to be released from the
secondary granules of activated neutrophils in the
presence of inflammation.1
We hypothesized that AF lactoferrin levels
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would be elevated in idiopathic PTL secondary to
decidual activation and that lactoferrin levels would
be even more elevated in PTL due to intraamniotic
infection (IAI).
SUBJECTS AND METHODS
AF samples were obtained from 186 pregnant
patients with intact membranes and no clinical-
evidence of chorioamnionitis. Approval for this in-
vestigation was obtained from the appropriate insti-
tutional review board, and written informed consent
was obtained from each patient. All specimens were
obtained by transabdominal amniocentesis under
continuous ultrasound guidance. The AF was trans-
ported to the laboratory in capped plastic syringes.
A portion ofthe fluid was sent to the research labora-
tory for microbiologic evaluation. AF cultures were
performed for aerobic and anaerobic bacteria, myco-
plasmas, Neisseria gonorrhoeae, and Chlamydia tracho-
matis, as previously described.3 The remaining
fluid was immediately centrifuged at 500-800 g for
10 min and the supernatant was stored at -70C
for later evaluation of lactoferrin levels.
Placentas were collected from all patients who
delivered within 72 h of amniocentesis and pro-
cessed as previously described. 13 Histologic chorio-
amnionitis was defined by the criteria of Salafia et
al. 14 The presence of grade inflammation (inflam-
matory cell invasion of at least 5 PMNs into the
amnion, chorion, subchorionic fibrin, or inner third
of the umbilical-vein wall) or greater in any of 3
placental sections examined was used to define his-
tologic chorioamnionitis. All specimens were exam-
ined by the same pathologist who was blinded to
the patient’s clinical course.
The AF samples previously stored at -70C
were thawed in batches, and the lactoferrin levels
were determined with an enzyme-linked immuno-
sorbent assay kit specific for lactoferrin (LEUKO-
ELISA, Techlab, Blacksburg, VA). This assay has
a detection limit of 4 ng/ml. The samples with lac-
toferrin levels above the upper limit of the assay’s
detection range were diluted and reassayed. The
interassay and intraassay coefficients of variation
were <10%. Lactoferrin assays were performed in
the research laboratory of Magee-Womens Re-
search Institute.
The patients were stratified into the following
4 groups based on clinical presentation:
Group 1: Term, no labor. Patients at ->37 weeks,
not in labor, undergoing amniocentesis for fetal lung
maturity studies prior to scheduled repeat cesarean
deliveries. N 50.
Group 2: Preterm, no labor. Patients at 24-36
weeks gestation, not in labor, who were undergoing
amniocentesis for genetic evaluation orAF bilirubin
studies. A patient was excluded if the karyotype
was abnormal or the fetus was subsequently found
to be affected by maternal isoimmunization.
N 52. An additional 29 samples were collected
from similar patients not in labor at 14-23 weeks
gestation. Data from these samples were excluded
from analysis with group 2, but were used in the
analysis of lactoferrin levels vs. gestational age.
Group 3: PTL with IAI. Patients inPTL at 24-34
weeks gestation with intact membranes and sub-
clinical IAI. Subclinical IAI was defined as a positive
AF culture or placental histologic chorioamnionitis
without clinical signs of infection. N 20.
Group 4: PTL without IAI. Patients in PTL at
24-34 weeks gestation with intact membranes and
without subclinical IAI. These patients had nega-
tive AF cultures and negative placental histology
(N 2) or negative AF cultures and no delivery
within 72 h of the amniocentesis (N 33). Total
N 35.
The exclusion criteria for all groups included
multiple gestation, evidence of rupture of the mem-
branes, diabetes, treatment with antibiotics within
the previous 7 days, the presence of any condition
requiring antimicrobial treatment, and abnormal
karyotype. Further exclusion criteria for groups 3
and 4 included gestational age of <24 weeks or
>34 weeks or cervical dilation >4 cm. Patients with
clinical evidence of chorioamnionitis as defined by
Gibbs et al.s were also excluded. PTL was defined
as the presence of regular uterine contractions with
a frequency of at least 10 contractions per hour and
observed cervical change.
Analysis of the data was performed on the statis-
tical program SYSTAT 5.2 for the Macintosh (SYS-
TAT, Inc., Evanston, IL). The Mann-Whitney U-
test was used for nonparametric comparison of AF
lactoferrin concentrations of the various groups.
The Pearson correlation coefficient was used to
evaluate the correlation between AF lactoferrin lev-
els and gestational age. Statistical significance was
defined as P < 0.05.
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Group
Fig. I. Median lactoferin levels standard error by patient
group. Group I: Term, 37-42 weeks gestation, no labor.
Group 2: Preterm, 24-36 weeks gestation, no labor. Group
3: Preterm labor, 24-34 weeks gestation, with IAI. Group
4: Preterm labor, 24-34 weeks gestation, without IAI. Group
vs. group 2, P < 0.0001; group 3 vs. group 4, P 0.057.
Group
Fig. 3. Median lactoferrin levels standard error in all
preterm patients at -<31 weeks gestation. Group 2: Preterm,
14-31 weeks gestation, no labor. Group 3: Preterm labor,
24-31 weeks gestation, with IAI. Group 4: Preterm labor,
24-31 weeks gestation, without IAI. Group 2 vs. groups 3
and 4, P 0.03; group 3 vs. group 4, P 0.005.
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Fig. 2. Lactoferrin levels vs. gestational age in all nonla-
boring patients. Significant relationship between lactoferrin
level and gestational age by Pearson correlation, P < 0.001.
RESULTS
The median lactoferrin levels in each group are
shown in Figure 1. The median level of lactoferrin
was low in nonlaboring preterm patients (group 2)
and significantly higher in nonlaboring patients at
term (group 1) (P < 0.0001). In the preterm pa-
tients, the median lactoferrin levels in the PTL
groups (groups 3 and 4) were significantly higher
than in nonlaboring preterm (PTL) patients (group
2) (P 0.002).
The effect of gestational age on lactoferrin levels
in nonlaboring patients is shown in Figure 2. Lacto-
ferrin levels are quite low prior to 32 weeks gesta-
tion and rise markedly from 32 weeks to term. When
we analyzed the data by the Pearson correlation, a
significant relationship between gestational age and
lactoferrin level was shown for nonlaboring patients
(P < 0.001). Because of the gestational age effect
illustrated in Figure 2, we analyzed the PTL data
at gestational ages of <32 weeks separately, as
shown in Figure 3. The median lactoferrin level in
the infected PTL group (group 3) was significantly
higher than in the noninfected PTL group (group 4)
(P 0.011), and both PTL groups had significantly
higher lactoferrin levels than the preterm, no labor
group (group 2) (P 0.03).
The results of cultures, histology, and lactoferrin
levels for the infected PTL group at <-31 weeks
gestation are shown in Table 1. In the PTL group
at <32 weeks gestation, a lactoferrin level of >2.5
pg/ml had a sensitivity of 100% for the identifica-
tion of a positive AF culture, with a specificity of
67%, a positive predictive value (PPV) of 46%, and
a negative predictive value (NPV) of 100%. This
same lactoferrin level of >2.5 lg/ml had a sensitiv-
ity of 82% for identification of positive histology,
with a specificity of 83%, a PPV of 82%, and a NPV
of 83%.
DISCUSSION
These data suggest that AF lactoferrin levels in
nonlaboring patients tend to be low, <2.5 lg/ml,
prior to 32 weeks gestation. After 31 weeks gesta-
tion up to term, the lactoferrin levels increase mark-
edly in nonlaboring patients. These findings are
consistent with the work of Niemela et al., lz who
measured lactoferrin levels in AF samples from 109
pregnancies at 14-42 weeks and found a striking
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 181AMNIOTIC-FLUID LACTOFERRIN HELLER ET AL.
TABLE I. Infected PTL group, <32 weeks
Gestational
age (weeks) Cx Organism
Placental Lactoferrin,
histology (lxg/ml)
28
29 + Fusobacterium nucleatum
28 + Mycoplasma hominis
28
29
29
24 + Gardnerella vaginalis
F. nucleatum
2 7 + M. hominis
F. nucleatum
26 + Candida albicans
30
29
+ 5.361
+ 4.879
+ 2.754
+ 0.788
+ 5.978
+ 2.589
+ 9.017
+ 9.341
+ 10.386
/ 0.907
/ 10.370
aCx AF culture results.
increase in AF lactoferrin levels in the third trimes-
ter. These workers also measured lactoferrin in nu-
merous fetomaternal tissues at term and found the
highest levels of lactoferrin were present in decidua
compared with amnion, chorion, trophoblast, um-
bilical cord, and fetal serum.
These findings suggest a role for lactoferrin in
the normal immune mechanisms of pregnancy. It
is known that lactoferrin plays a protective role by
interfering with the bacterial utilization of iron mol-
ecules crucial for cell growth and metabolism. 16’17
Lactoferrin also has bacteriostatic and bacteriocidal
effects in a wide range oforganisms, including gram-
positive and gram-negative bacteria, aerobes, anaer-
obes, and yeasts.
18 The iron-lactoferrin complex
may also provide iron that is necessary for catalyzing
the production of free radicals, resulting in the kill-
ing of phagocytized bacteria. 19’z Further evidence
supporting the role of lactoferrin in the inflamma-
tory reaction comes from the clinical arena where
it is known that patients lacking specific granules
in their neutrophils have recurrent bacterial infec-
tions, zl These data suggest that lactoferrin plays a
protective role against invading pathogens in the
AF of late pregnancy. We also postulate that the
source of the increasing AF lactoferrin in the third
trimester of normal pregnancy is the decidua and
that rising lactoferrin levels after 31 weeks gestation
are a marker for decidual activation in possible prep-
aration for term labor. Lactoferrin levels may rise
after 31 weeks in preparation for the inevitable inva-
sion of pathogens which will accompany the normal
labor process.
Our data also show that AF lactoferrin levels are
markedly elevated in PTL patients with IAI at <32
weeks gestation. This finding was not related to
increasing gestational age. We propose that the
source of lactoferrin in these patients is the second-
ary granules of activated neutrophils, and the find-
ing of elevated AF lactoferrin at <32 weeks gesta-
tion is a marker for IAI. Since lactoferrin levels are
normally quite low at these gestational ages, we
propose that these patients are at increased risk
for IAI because they lack the protective effect of
decidual lactoferrin which normally increases at
about 32 weeks.
Using a lactoferrin level of >2.5 txg/ml, we were
able to identify all of the patients at <32 weeks
with positive AF cultures. We propose that an AF
lactoferrin higher than this critical value at gesta-
tions of <32 weeks is highly suggestive of IAI.
We recognize the limitations of our current tech-
nology in identifying those PTL patients without
clinical evidence of chorioamnionitis who actually
have an infectious etiology for their PTL. We used
the most widely reported methods in the literature
for identifying IAI: AF culture and placental histo-
logic chorioamnionitis. The AF culture is positive
in a minority (0-26%) of PTL patients with intact
membranes1 and may not reflect infectious events
occurring in the decidua or membranes. The pla-
cental histology at delivery may not be an accurate
reflection of the events which initiated PTL. De-
spite the limitations of these methods, our data add
further to the evidence supporting the hypothesis
that PTL has an infectious etiology.
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Further study of the role of lactoferrin in normal
and abnormal gestation is required. In particular,
the source of lactoferrin (decidua vs. neutrophil) in
various clinical situations must be determined. The
results of this study lend further support to theories
suggesting infection as a major cause ofPTL, espe-
cially in very preterm gestations. The AF lactoferrin
assay may prove to be a useful tool to clinicians in
selecting those PTL patients at <32 weeks gesta-
tion who may benefit from closer observation, early
delivery, or antimicrobial therapy.
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